<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920478</url>
  </required_header>
  <id_info>
    <org_study_id>GN09RH196</org_study_id>
    <secondary_id>CSO - CAF / 08 / 03</secondary_id>
    <nct_id>NCT00920478</nct_id>
  </id_info>
  <brief_title>Targeting Synovitis in Early Rheumatoid Arthritis</brief_title>
  <acronym>TaSER</acronym>
  <official_title>Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis - a Randomised Study With Blinded Outcome Assessments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chief Scientist Office of the Scottish Government</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Medicine Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NHS Greater Glasgow and Clyde</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with rheumatoid arthritis are at risk of developing permanent joint damage and&#xD;
      disability. This study hopes to identify the most effective way of using existing arthritis&#xD;
      medication to minimise the chances of developing permanent disability. Patients will have&#xD;
      their arthritis activity assessed using an ultrasound machine. If there is still evidence of&#xD;
      active arthritis the participant's arthritis medication will be increased until the arthritis&#xD;
      is in remission. The effectiveness of this approach will be compared to the traditional&#xD;
      method of assessing arthritis using clinical examination.&#xD;
&#xD;
      Furthermore, it is extremely important to identify those patients most at risk of aggressive&#xD;
      disease. The investigators hope to produce a more accurate measurement of disease prognosis&#xD;
      by examining the relationship between a series of blood tests and how well controlled&#xD;
      rheumatoid arthritis appears after 18 months of therapy. Some patients will also be asked to&#xD;
      donate samples of joint fluid and joint lining for additional analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURPOSE 1 - to determine whether it is possible to achieve better control of inflammatory&#xD;
      joint disease activity in early rheumatoid arthritis by using musculoskeletal ultrasound,&#xD;
      instead of clinical examination, to identify the presence, or absence, of synovitis&#xD;
&#xD;
      NULL HYPOTHESIS 1 - using musculoskeletal ultrasound to confirm / refute the presence of&#xD;
      ongoing synovitis will NOT allow better control of early rheumatoid arthritis nor prevent&#xD;
      progression of destructive joint disease despite patients receiving more intensive disease&#xD;
      modifying therapy regimens&#xD;
&#xD;
      PURPOSE 2 - to determine whether baseline measures of certain biochemical and pathological&#xD;
      factors, associated with the development of inflammatory synovitis, are predictive of&#xD;
      response to therapy in early rheumatoid arthritis and short term outcome measures of&#xD;
      inflammatory joint disease activity, functional ability and quality of life&#xD;
&#xD;
      NULL HYPOTHESIS 2 - serial measures of biochemical and pathological factors, associated with&#xD;
      the development of inflammatory synovitis, will NOT correlate with short term outcome&#xD;
      measures of disease activity and therefore cannot be used to predict a patient's prognosis&#xD;
      nor identify those at risk of progressive, destructive joint disease&#xD;
&#xD;
      TRIAL DESIGN - randomised, prospective single blinded trial of treatment strategy with a&#xD;
      nested study correlating baseline measures and 18 month outcomes&#xD;
&#xD;
      Investigators will not be blinded to treatment group. Treatment decisions and escalation of&#xD;
      therapy will be dictated by a standardised protocol. The sequence of therapy escalation will&#xD;
      be identical for both groups. The groups will differ on the threshold needed to progress to&#xD;
      the next treatment step&#xD;
&#xD;
      Assessors of disease activity, radiological and pathological outcomes will be blinded to&#xD;
      treatment group and their findings will form the basis of each groups final outcome measures&#xD;
&#xD;
      TREATMENT PROTOCOL - the sequence of therapy escalation will be the same for each group. The&#xD;
      groups differ by the 'trigger' required to progress to the next treatment step. Therapy will&#xD;
      escalated in each group if the measured disease activity exceeds that groups threshold&#xD;
      trigger. Changes in DMARD therapy doses and/or combinations take three months to reach&#xD;
      maximum effect; therefore, at least a three month gap will be left between each treatment&#xD;
      escalation&#xD;
&#xD;
      PRIMARY OUTCOME MEASURE&#xD;
&#xD;
        1. Magnetic Resonance Imaging of Dominant Wrist - baseline and 18 months. Images will be&#xD;
           scored using the OMERACT RAMRIS(Rheumatoid Arthritis Magnetic Resonance Imaging Score)&#xD;
           atlas. The change in each patient's synovitis and erosion scores will be pooled and&#xD;
           compared for each intervention group&#xD;
&#xD;
        2. 44 joint Disease Activity Score - Mean change of DAS44 with time will represent the rate&#xD;
           of response to treatment. Mean area under curve DAS44 will represent overall level of&#xD;
           disease activity throughout the study period&#xD;
&#xD;
      SECONDARY OUTCOME MEASURES&#xD;
&#xD;
        1. European League Against Rheumatism Response Rates - A EULAR Good response is defined as&#xD;
           a greater than 1.2 change in DAS44 and a final DAS44 less than 2.4. Disease remission is&#xD;
           defined as DAS44 less than 1.6&#xD;
&#xD;
        2. Functional Measures - Health Assessment Questionnaire and EuroQoL-5D questionnaires at&#xD;
           enrollment and then every 3 months.&#xD;
&#xD;
        3. Plain Xrays - plain xrays of hands, wrists and feet at baseline and 18 months. Change in&#xD;
           Sharp score between baseline and 18 month films will be reported&#xD;
&#xD;
        4. Biomarker analysis - analyses will include specific genetic factors(genomic DNA), gene&#xD;
           expression (RNA analysis), novel autoantibody assays, cytokine / emerging inflammatory&#xD;
           protein profiling, lipid / lipoprotein based markers, metabolic assays and assessment of&#xD;
           bone and cartilage turnover markers.&#xD;
&#xD;
      Samples will be collected at baseline, 3 months and 12 months (if not commenced on&#xD;
      etanercept), immediately before commencing etanercept, 3 months and 6 months after commencing&#xD;
      etanercept and 3 months after cessation. Final disease outcome measures for each patient will&#xD;
      be correlated with baseline biomarker values to determine if any predictive relationships&#xD;
      exist.&#xD;
&#xD;
      All values will be entered into a logistical regression analysis to try and create a&#xD;
      statistical predictive model. Serial biomarker analyses will demonstrate how the different&#xD;
      components of the pathogenetic process respond to the different stages of DMARD therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI RAMRIS Erosion Score</measure>
    <time_frame>Baseline and 18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>44 Joint Disease Activity Score</measure>
    <time_frame>Baseline, 3, 6, 9, 12, 15 and 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plain Xray - Hands and Feet - modified Sharp score</measure>
    <time_frame>Baseline and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire</measure>
    <time_frame>Baseline, 3, 6, 9, 12, 15 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro-Qol 5D</measure>
    <time_frame>Baseline, 3, 6, 9, 12, 15 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EULAR response and remission rates</measure>
    <time_frame>Baseline and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis - correlation between baseline values and 18 month radiological outcomes</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rates</measure>
    <time_frame>Throughout period of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Polyarthritis</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inflammatory disease activity assessed using DAS28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultrasound Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inflammatory disease activity assessed using musculoskeletal ultrasound (gray scale and power doppler)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Musculoskeletal Ultrasound</intervention_name>
    <description>Gray scale and power doppler - to identify the presence of synovitis</description>
    <arm_group_label>Ultrasound Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>28 Joint Disease Activity Score</intervention_name>
    <description>Clinical assessment of synovitis - composite score incorporating 28 tender joint count, 28 swollen joint count, erythrocyte sedimentation rate and patient global VAS</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients attending Early RA clinics with newly diagnosed RA or anti-CCP +ve&#xD;
             Undifferentiated Arthritis (UA)&#xD;
&#xD;
          2. Active disease (DAS28 &gt; 3.2)&#xD;
&#xD;
          3. DMARD naïve or DMARD monotherapy for less than 6 weeks&#xD;
&#xD;
          4. Aged 18 or more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant liver disease and/or abnormality of liver function tests&#xD;
&#xD;
          2. AST / ALT &gt; x2 normal, Alkaline Phosphatase &gt; x2.5 normal&#xD;
&#xD;
          3. Renal impairment - serum creatinine &gt; 200 μmol/l, eGFR &lt; 30&#xD;
&#xD;
          4. Cytopenias - white cell count &lt; 4.0, haemoglobin &lt; 10, platelet &lt; 150&#xD;
&#xD;
          5. Pregnancy or planned pregnancy&#xD;
&#xD;
          6. Contraindication to MRI&#xD;
&#xD;
          7. Other co-morbid condition that in the opinion of the investigator would preclude the&#xD;
             use of sequential or combination DMARD therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duncan R Porter, MBChB, MRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Gartnavel General Hospital, Glasgow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James E Dale, MBChB, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iain B McInnes, PhD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James Dale, MBChB, MRCP</last_name>
    <phone>+44 141 211 3000</phone>
    <phone_ext>3008</phone_ext>
    <email>james.dale@ggc.scot.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Rheumatology, Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan Porter, MBChB</last_name>
      <phone>+44 141 211 3000</phone>
      <email>duncan.porter@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Duncan Porter, MBChB, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Stobhill Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G21 3UW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilary Wilson, MD, MRCP</last_name>
      <phone>+44 141 211 3307</phone>
      <email>hilary.wilson@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Hilary Wilson, MD, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Rheumatic Diseases, Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David McCarey, MBChB, FRCP</last_name>
      <phone>+44 141 2114965</phone>
      <email>david.mccarey@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>David McCarey, MD, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>June 11, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2009</study_first_posted>
  <last_update_submitted>September 9, 2009</last_update_submitted>
  <last_update_submitted_qc>September 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr James Dale</name_title>
    <organization>University of Glasgow and National Health Service</organization>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Musculoskeletal Ultrasound</keyword>
  <keyword>Synovitis</keyword>
  <keyword>DMARD</keyword>
  <keyword>Etanercept</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Undifferentiated Inflammatory Polyarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Synovitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

